StockData
10x Genomics, Inc. logo

10x Genomics, Inc. (TXG) stock

TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30106% above fair value
$56.30+1.31 (+2.38%)

Close on Nov 17, 2026Market cap $7.34BP/E –Yield –

10x Genomics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

10x Genomics's price to sales ratio was 12.8× on Nov 11, 2026, against 3.6× a year earlier. Over the last 5 years it ranged from 1.7× to 35.4×, with a median of 7.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202612.8×+9.7
2025Dec 31, 20253.1×+0.4
2024Dec 31, 20242.7×−8.3
2023Dec 29, 202311.0×+2.8
2022Dec 30, 20228.2×−27.2
2021Dec 31, 202135.4×−21.7
2020Dec 31, 202057.1×+24.0
2019Dec 31, 201933.1×–

More 10x Genomics figures

See a number that looks wrong?